跳转至内容
Merck
CN

SAB4200130

Sigma-Aldrich

Anti-Phospholipase A2 (iPLA2) (C-terminal region) antibody produced in rabbit

enhanced validation

~1.5 mg/mL, affinity isolated antibody

登录查看公司和协议定价

别名:
Anti-CaI-PLA2, Anti-INAD1, Anti-IPLA2-VIA, Anti-PARK14, Anti-PLA2, Anti-PLA2G6, Anti-PNPLA9, Anti-Phospholipase A2, group VI (cytosolic, calcium-independent), GVI
MDL编号:
UNSPSC代码:
12352203
NACRES:
NA.41

生物来源

rabbit

偶联物

unconjugated

抗体形式

affinity isolated antibody

抗体产品类型

primary antibodies

克隆

polyclonal

形式

buffered aqueous solution

分子量

antigen ~85 kDa
antigen ~95 kDa

种属反应性

mouse, human, rat

包装

antibody small pack of 25 μL

增强验证

recombinant expression
Learn more about Antibody Enhanced Validation

浓度

~1.5 mg/mL

技术

western blot: 1-2 μg/mL using extract of HEK-293T cells overexpressing human iPLA2, and 1-2 mg/mL using rat kidney extract (S1 fraction).
western blot: 1-2 μg/mL using rat kidney extract (S1 fraction)

UniProt登记号

运输

dry ice

储存温度

−20°C

靶向翻译后修饰

unmodified

基因信息

human ... PLA2G6(8398)

一般描述

Ca2+-independent phospholipase A2 (iPLA2), also known as PLA2G6, is a member of the PLA2 superfamily. It consists of a C-terminal calmodulin-binding domain, a bipartite nuclear localization sequence, GXSXG serine lipase residues, and ankyrin repeats at the N-terminus. iPLA2 gene is mapped to human chromosome 22q13.1 and encodes alternatively spliced isoforms.

特异性

Anti-Phospholipase A2 (iPLA2) (C-terminal region), specifically recognizes human and rat iPLA2.

应用

Anti-Phospholipase A2 (iPLA2) (C-terminal region) antibody produced in rabbit has been used in immunoblotting.

生化/生理作用

Ca2+-independent phospholipase A2 (iPLA2) catalyzes the cleavage of fatty acids from the sn-2 position of phospholipids. iPLA2 is implicated in leukotriene and prostaglandin production as well as in arachidonic acid release phospholipid remodeling. Mutations in the PLA2G6 gene are the cause of two childhood neurologic disorders, neurodegeneration with brain iron accumulation (NBIA) and infantile neuroaxonal dystrophy 1 (INAD1). Recent evidence suggests that both Ca2+-dependent PLA2 (cPLA2) and iPLA2 may play a central role in memory deficits at early stages.

外形

Solution in 0.01 M phos­phate buffered saline, pH 7.4, containing 15 mM sodium azide.

储存及稳定性

Store at −20 °C. For continuous use, the product may be stored at 2−8 °C for up to one month. For extended storage, freeze at −20 °C in working aliquots. Repeated freezing and thawing, or storage in “frost-free” freezers, is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation. Discard working dilutions if not used within 12 hours.

免责声明

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

闪点(°F)

Not applicable

闪点(°C)

Not applicable

法规信息

常规特殊物品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Zhengshan Zhao et al.
PloS one, 6(10), e26991-e26991 (2011-11-03)
Infantile neuroaxonal dystrophy (INAD) is a progressive, autosomal recessive neurodegenerative disease characterized by axonal dystrophy, abnormal iron deposition and cerebellar atrophy. This disease was recently mapped to PLA2G6, which encodes group VI Ca(2+)-independent phospholipase A(2) (iPLA(2) or iPLA(2)β). Here we
Evelin L Schaeffer et al.
Psychopharmacology, 198(1), 1-27 (2008-04-09)
Alzheimer disease (AD), a progressive neurodegenerative disorder, is the leading cause of dementia in the elderly. A combination of cholinergic and glutamatergic dysfunction appears to underlie the symptomatology of AD, and thus, treatment strategies should address impairments in both systems.
Laura A Engel et al.
PloS one, 5(9), e12897-e12897 (2010-10-05)
Mutations in the PLA2G6 gene have been identified in autosomal recessive neurodegenerative diseases classified as infantile neuroaxonal dystrophy (INAD), neurodegeneration with brain iron accumulation (NBIA), and dystonia-parkinsonism. These clinical syndromes display two significantly different disease phenotypes. NBIA and INAD are
Mariska Davids et al.
Journal of medical genetics, 53(3), 180-189 (2015-12-17)
Mutations in PLA2G6, which encodes the calcium-independent phospholipase A2 group VI, cause neurodegeneration and diffuse cortical Lewy body formation by a yet undefined mechanism. We assessed whether altered protein glycosylation due to abnormal Golgi morphology might be a factor in
Neil V Morgan et al.
Nature genetics, 38(7), 752-754 (2006-06-20)
Neurodegenerative disorders with high brain iron include Parkinson disease, Alzheimer disease and several childhood genetic disorders categorized as neuroaxonal dystrophies. We mapped a locus for infantile neuroaxonal dystrophy (INAD) and neurodegeneration with brain iron accumulation (NBIA) to chromosome 22q12-q13 and

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门